Trial reportEuropean eating disorders review : the journal of the Eating Disorders Association2012
Double-blind placebo-controlled trial of quetiapine in anorexia nervosa.
Trial report in European eating disorders review : the journal of the Eating Disorders Association, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00518973 (Double-blind Placebo-controlled Trial of Quetiapine in Anorexia Nervosa), which is not on this map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Double-blind Placebo-controlled Trial of Quetiapine in Anorexia Nervosa
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- The Efficacy of Pharmacological Treatment of Depression in Anorexia Nervosa and Underweight Patients: A Systematic Review.European eating disorders review : the journal of the Eating Disorders Association · 2026Pooled it
- A Meta-Analysis of Dropout and Metabolic Effects of Antipsychotics in Anorexia Nervosa.Frontiers in psychiatry · 2020Pooled it
- Use of atypical antipsychotics in individuals with anorexia nervosa.The mental health clinician · 2025Article
- Review
- Atypical antipsychotic use does not impact weight gain for individuals with extreme anorexia nervosa: a retrospective case-control study.Journal of eating disorders · 2023Article
- Antipsychotic effects on anthropometric outcomes in anorexia nervosa: a retrospective chart review of hospitalized children and adolescents.Journal of eating disorders · 2023Article
- Pharmacotherapy, alternative and adjunctive therapies for eating disorders: findings from a rapid review.Journal of eating disorders · 2023Review
- Efficacy and tolerance of second-generation antipsychotics in anorexia nervosa: A systematic scoping review.PloS one · 2023Article
- Pharmacotherapeutic strategies for the treatment of anorexia nervosa - too much for one drug?Expert opinion on pharmacotherapy · 2020Review
- Medication in AN: A Multidisciplinary Overview of Meta-Analyses and Systematic Reviews.Journal of clinical medicine · 2019Review
- Pharmacotherapy of eating disorders.Current opinion in psychiatry · 2017Review
- Comparison of associated features and drug treatment between co-occurring unipolar and bipolar disorders in depressed eating disorder patients.BMC psychiatry · 2017Article
- The Role of Psychotropic Medications in the Management of Anorexia Nervosa: Rationale, Evidence and Future Prospects.CNS drugs · 2016Review
- Psychopharmacologic treatment of eating disorders: emerging findings.Current psychiatry reports · 2015Review
- Pharmacological manipulations in animal models of anorexia and binge eating in relation to humans.British journal of pharmacology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveOur objective is to determine whether quetiapine was superior to placebo in increasing weight or reducing core symptoms of anorexia nervosa as assessed by the Yale-Brown-Cornell Eating Disorder Scale and the Eating Disorder Inventory-2.
methodParticipants were randomised to 8 weeks of quetiapine or placebo.
resultsThere are 21 participants who signed informed consent, 15 were randomised, 14 returned for at least one visit after receiving drug and 10 completed the study. There were no differences between drug and placebo in questionnaire scores, weight or measures of anxiety or depression. DISCUSSION: There was no difference between quetiapine and placebo on weight gain or core symptoms. Small effect sizes suggest that a higher number of participants would not increase significant differences between groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.